XML 114 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Narrative) (Details)
 1 Months Ended 12 Months Ended
Jun. 15, 2023
USD ($)
Mar. 31, 2023
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
product_target
$ / shares
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Accounts receivable         $ 923,000 $ 3,678,000      
General and administrative expense         61,167,000 62,682,000 $ 63,219,000    
Biogen MA, Inc.                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Change in estimate of transaction price, increase in revenue $ 127,100,000                
Biogen MA, Inc. | License and Service                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Fixed consideration                 $ 204,600,000
Remaining performance obligation amount         0 151,300,000      
Cumulative catch-up to expense   $ 2,500,000              
General and administrative expense         2,600,000 400,000 $ 600,000    
Biogen MA, Inc. | Stock Purchase Agreement                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Sale of stock, number of shares issued in transaction (in shares) | shares       24,420,157          
Sale of stock, price per share (in dollars per share) | $ / shares       $ 9.2137          
Consideration received from sale of stock       $ 225,000,000          
Sale of stock, excess consideration received on transaction       79,600,000          
Collaboration agreement, equity issued       145,400,000          
Accounts receivable         0 500,000      
Deferred revenue         0 $ 132,200,000      
Biogen MA, Inc. | Collaboration and License Agreement                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Proceeds from collaborators     $ 125,000,000 $ 125,000,000          
Number of neurological disease gene targets selected by counterparty (in product targets) | product_target       4          
Number of additional neurological disease gene targets | product_target       7          
Collaborative arrangement transaction price $ (17,300,000)                
Collaboration arrangement, commission fee, portion of gross proceeds, value               $ 7,000,000  
Collaborative agreement, percent of initial recognition       2.00%          
Contract with customer, asset, after allowance for credit Loss         $ 4,100,000